8 Week Multi-site Study of MYDAYIS® for Bipolar Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-17

Study Completion Date

2025-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol is a Phase 2 multi-site study which aims to evaluate the safety and effectiveness of MYDAYIS\® as adjunctive therapy for adults with bipolar depression. Results from this study WILL NOT be used to contribute to an approval of MYDAYIS \® for this indication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression

NCT01093963

Bipolar Depression

TERMINATED PHASE3

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01072630

Depression

COMPLETED PHASE3

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01121536

Depression

TERMINATED PHASE3

A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01072929

Depression

COMPLETED PHASE3

Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

NCT01131559

Bipolar Depression

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study subjects will be randomized to receive MYDAYIS® or placebo on a 1:1 ratio according to computer-generated coding. Each site will have its own randomization list. Allocation concealment will be achieved by having the research pharmacy perform the randomization, package the study medication, and maintain the integrity of the blinded information throughout the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mydayis - Active

MYDAYIS®, Oral administration, dose regimen for Double blind phase and open label phase.

12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days

Group Type ACTIVE_COMPARATOR

Mydayis Extended-Release Capsule

Intervention Type DRUG

Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®

Placebo

Matching placebo, Oral administration, dose regimen for Double blind phase and open label phase.

12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mydayis Extended-Release Capsule

Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®

Intervention Type DRUG

Placebo

Matching placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

d-amphetamine / l-amphetamine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female between 18 and 55 years of age
2. Bipolar I or II disorder as confirmed by structured diagnostic interview by Axis I of the SCID by DSM-IV-TR.
3. Currently experiencing a major depressive episode unresponsive to stable (i.e. at least 4 weeks) anti-manic mood stabilizers (lithium, valproate) and/or antipsychotic therapy, with or without concomitant antidepressant therapy.
4. Symptom severity score ≥11 on the self-report version of the Quick Inventory for Depressive Symptomatology (QIDS-SR16) or score ≥11 on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) and ≥ 3 on the Clinical Global Impression for Bipolar Illness (CGI-BP) Depression Severity Scale.
5. Patients with a comorbid attention deficit disorder and binge eating disorder will be included.
6. Patients will be allowed to continue with their behavioral treatments (ie. CBT) targeted at their primary diagnosis.

Exclusion Criteria

1. Ability to provide informed consent and understand fully English and score ≥ 90% on comprehension test questionnaire that reviews study goals.
2. Clinically significant signs of suicidality from any of the following assessments:

1. Response ≥ 4 on MADRS question # 10
2. Response ≥2 on QIDS-C or QIDS-SR question # 12
3. Yes response on Columbia Suicide Severity Scale (CSSR) Question # 3 (ideation without plan or intent) ,Question #4 (ideation with intent, but no plan), or Question # 5 (ideation, intent, and plan)
4. Suicide attempt within the past year, as defined by the Columbia-Suicide Severity Scale
3. Known lifetime history of DSM-IV-TR diagnosis of cocaine or methamphetamine abuse or dependence. Nicotine dependence will be an exception.
4. Positive toxicology screen for drugs of abuse (ie. cocaine, methamphetamine, cannabis, opiates)
5. Known history of prescription abuse of stimulants.
6. Lifetime history of stimulant-induced mania
7. Active abuse or dependence of alcohol, opiates or cannabis that is either current or less than 3 months full remission.
8. Baseline Young Mania Rating Scale (YMRS) score ≥ 8
9. Patients with active psychosis identified by SCID or a diagnosis of schizophrenia, schizoaffective disorder, delusional or schizophreniform disorder.
10. Known hypersensitivity, such as angioedema or anaphylaxis, to amphetamines or other ingredients of MYDAYIS.
11. Clinically unstable medical disease
12. Known history of a structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormality, coronary artery disease, stroke or other serious cardiovascular problems.
13. ECG with significant arrhythmias, conduction abnormalities, or voltage criteria met for left ventricular hypertrophy (unless cleared by cardiology consultation).
14. Uncontrolled hypertension (\>160/100) or tachycardia (heart rate \>110)
15. History of grand mal seizure; history of febrile seizure as infant permitted
16. Established vasculopathy or history of Raynaud's phenomena
17. Narrow angle glaucoma
18. Patients with end stage renal disease (ESRD).
19. Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within 14 days following discontinuation of treatment with a monoamine oxidase inhibitor.
20. Tourette's syndrome
21. Women who are pregnant, lactating or of child-bearing potential and not using at least one adequate contraceptive measure (i.e. hormonal contraception-birth control pills-, intrauterine devices (IUD), tubal ligation or condoms during sexual intercourse)
22. Men who do not use adequate measures (male condoms).

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No